China channel feed

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

11 months ago
Financing
Pharma

Up­dat­ed: With a promis­ing new Keytru­da con­tender, Sum­mit pre­pares to spar with Mer­ck

11 months ago
R&D
Pharma

Gen­Fleet high­lights Phase 2 da­ta on KRAS/EGFR com­bo in lung can­cer 

11 months ago
R&D

BioN­Tech dou­bles down on ADC part­ner MediLink in new $1.8B biobucks pact

11 months ago
Startups
Deals

Nu­va­tion Bio shares piv­otal Chi­na da­ta for can­cer drug from An­Heart buy­out

11 months ago
R&D

Mer­ck KGaA avoids pros­e­cu­tion af­ter co­op­er­at­ing with DOJ to un­cov­er Chi­na ex­port scheme

11 months ago
Law

Take­da en­ters hot mol­e­c­u­lar glue space in up to $1.2B pact with De­gron

11 months ago
Startups
Pharma

AGC Bi­o­log­ics, Bio­Con­nec­tion forge part­ner­ship to be an al­ter­na­tive to WuXi

11 months ago
Manufacturing

With $5B in Chi­na sales, As­traZeneca dou­bles down on Chi­nese bio­phar­ma in­no­va­tion

11 months ago
Pharma

Ex­clu­sive: Mem­bers of Con­gress buy and sell stocks that would gain from bill ban­ning Chi­na biotech com­pa­nies

11 months ago

Bain, At­las, RTW back new biotech de­vel­op­ing obe­si­ty drugs with $400M

11 months ago
Startups

BeiGene looks at new part­ner­ships, with a full can­cer pipeline and grow­ing foot­print

11 months ago
Deals
Pharma

New Biose­cure draft fea­tures 2032 grand­fa­ther clause, five-year grace pe­ri­od for added com­pa­nies

12 months ago
Pharma
FDA+

BIO CEO de­fends the or­ga­ni­za­tion's about-face on the Biose­cure Act

12 months ago
Deals

Charles Riv­er touts first-quar­ter man­u­fac­tur­ing rev­enue, says Chi­na bill is ‘net pos­i­tive’

12 months ago
Manufacturing

In­novent says next-gen GLP-1 drug from Lil­ly beats top di­a­betes med in Phase 3 Chi­na study

12 months ago
R&D

Law­mak­ers con­sid­er lim­it­ing how long ex­ist­ing WuXi con­tracts can con­tin­ue

Last year
Deals
Discovery

BeiGene ear­marks $74M to build fourth fa­cil­i­ty in Chi­na

Last year
Manufacturing

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Last year
Cell/Gene Tx
In Focus

House Over­sight chair press­es FDA on Chi­na amid grow­ing ten­sions

Last year
FDA+

House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

Last year
Pharma

WuXi wants to re­gain client con­fi­dence amid claims of IP trans­fer to Chi­nese au­thor­i­ties 

Last year
Manufacturing

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Last year
R&D

Ther­mo Fish­er ex­pects last­ing ben­e­fits to bill tar­get­ing Chi­nese ser­vice providers

Last year
Manufacturing
First page Previous page 3456789 Next page Last page
A service from the Financial Times